In recent years, significant progress has been made in molecular targeted therapy, with targeted inhibitors for driver gene mutations such as EGFR, ALK, and ROS1 (e.g., EGFR-TKI, ALK-TKI) becoming standard treatment options for advanced NSCLC (9, 10). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.